- Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
-
Gedallovich SM, Kwo PY
- KMID: 2560126
- Clin Mol Hepatol.
- 2024 Oct;30(4):1050-1052.
- doi: 10.3350/cmh.2024.0546
-
- CITED
-
- Close
- SHARE
-
- Close
- Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
-
Kwo PY
- KMID: 2560078
- Clin Mol Hepatol.
- 2024 Oct;30(4):714-717.
- doi: 10.3350/cmh.2024.0425
-
- CITED
-
- Close
- SHARE
-
- Close
- Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
-
Gedallovich SM, Kwo PY
- KMID: 2560069
- Clin Mol Hepatol.
- 2024 Oct;30(4):677-681.
- doi: 10.3350/cmh.2024.0418
-
- CITED
-
- Close
- SHARE
-
- Close
- Current and future strategies for the treatment of chronic hepatitis C
-
Alshuwaykh O, Kwo PY
- KMID: 2514764
- Clin Mol Hepatol.
- 2021 Apr;27(2):246-256.
- doi: 10.3350/cmh.2020.0230
Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct... -
- CITED
-
- Close
- SHARE
-
- Close
- The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
-
Kwo PY, Vinayek R
- KMID: 2284229
- Gut Liver.
- 2011 Dec;5(4):406-417.
The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher... -
- CITED
-
- Close
- SHARE
-
- Close
